Letters sent to healthcare professionals in October 2015
In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib
A has been sent to inform about the risk of cardiac failure.
A has been sent to inform about the risk of potentiation of radiation toxicity.
Article citation: Drug Safety Update Vol 9 issue 4, November 2015: 3.
Updates to this page
Published 12 November 2015